A Silk-Based Skin Spray, Cleared as a Device

The material has a different job

New Day Skin Spray received an FDA 510(k) substantial-equivalence decision in January 2026. Its FDA record describes a prescription skin emulsion for managing skin dryness and atopic dermatitis and maintaining a moist skin or wound environment. The device classification is “Dressing, Wound, Drug”; the record also marks it as a combination product. This is device clearance through a predicate pathway, not approval of a new medicine. ^{[1, 2]}

The FDA summary lists silk fibroin among the ingredients and describes a breathable layer formed on the skin. In an August launch announcement, Evolved By Nature calls its input a “soluble silk fibroin peptide.” These are two source-specific descriptions of the material; the company’s peptide language should not be presented as an FDA finding. Here the formulation’s stated role is barrier protection and moisturization, rather than delivery of a named therapeutic payload into tissue. ^{[2, 3]}

Clearance answers a defined question

The FDA summary describes formulation, batch-consistency, microbiological and biocompatibility testing. It does not present a randomized clinical comparison showing superiority to existing atopic dermatitis treatments. The January clearance and the company’s August market announcement are separate events. ^{[1, 2, 3]}

For product developers, the useful distinction is between a material’s name and its actual job in the finished product. A silk-based surface barrier must be judged by its defined use, device performance and tolerability. Evidence for a different delivery claim would require a different test plan.

Sources

1. U.S. Food and Drug Administration. New Day Skin Spray, 510(k) K252568, decision January 23, 2026.
2. U.S. Food and Drug Administration. 510(k) Summary: New Day Skin Spray, K252568.
3. Evolved By Nature. Peptide Platform Used in FDA-Cleared Prescription Therapy for the Management of Atopic Dermatitis. August 20, 2026.